Exagen Inc. (XGN)
3.02
-0.10 (-3.21%)
At close: Jan 14, 2025, 3:59 PM
3.00
-0.66%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 2.84 |
| Market Cap | 53.26M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -3.21 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.27 |
| Volume | 238,221 |
| Avg. Volume (20D) | 118,606 |
| Open | 3.12 |
| Previous Close | 3.12 |
| Day's Range | 2.92 - 3.18 |
| 52-Week Range | 1.30 - 6.22 |
| Beta | undefined |
About XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables diff...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Sep 19, 2019
Employees 174
Stock Exchange NASDAQ
Ticker Symbol XGN
Website https://www.exagen.com
Analyst Forecast
According to 2 analyst ratings, the average rating for XGN stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 148.34% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Exagen Inc. is scheduled to release its earnings on Mar 17, 2025,
before market opens.
Analysts project revenue of $13.68M, reflecting a -0.62% YoY shrinking and earnings per share of -0.24, making a -22.58% decrease YoY.
Analysts project revenue of $13.68M, reflecting a -0.62% YoY shrinking and earnings per share of -0.24, making a -22.58% decrease YoY.
5 months ago ·
Source
+12.65%
Exagen shares are trading higher after the company...
Unlock content with
Pro Subscription
10 months ago ·
Source
+9.26%
Exagen shares are trading higher after the company reported better than expected Q4 FY2023 earnings and issued FY2024 guidance.
